9 5 9 0 3
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
IL-2 -330T/G 多态性与癌症风险: 一项综合分析
Authors Zhao HY, Wang R
Published Date July 2015 Volume 2015:8 Pages 1753—1760
DOI http://dx.doi.org/10.2147/OTT.S86136
Received 6 April 2015, Accepted 14 May 2015, Published 17 July 2015
Purpose: Some studies have investigated the association of IL-2 -330T/G (rs2069762)
polymorphism with cancer risk, but the previous results were conflicting and
had relatively low statistical power. Thus, we performed a meta-analysis to
derive a more precise estimation of the association between IL-2 -330T/G polymorphism and
cancer risk.
Methods: A literature search was performed systematically using electronic databases. The odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect.
Results: A total of ten studies including 3,060 cases and 3,435 controls were involved in this meta-analysis. The results indicated that IL-2 -330T/G polymorphism was significantly associated with cancer risk ([OR =2.03, 95% CI =1.40–2.95] for GG vs TT; [OR =1.37, 95% CI =1.11–1.69] for GT vs TT; [OR =1.46, 95% CI =1.18–1.81] for [GG + GT] vs TT; [OR =1.66, 95% CI =1.24–2.23] for GG vs [GT + TT]; and [OR =1.35, 95% CI =1.16–1.57] for G vs T). In the subgroup analysis according to cancer type, significant association was found in lymphoma ([OR =1.46, 95% CI =1.11–1.91] for GT vs TT; [OR =1.58, 95% CI =1.22–2.05] for [GG + GT] vs TT; [OR =1.84, 95% CI =1.22–2.77] for GG vs [GT + TT]) and other cancers, but not in gastric cancer. In the subgroup analysis by ethnicity, the significant risk was found among Asians, but not among Europeans.
Conclusion: This meta-analysis suggests that IL-2 -330T/G polymorphism has an increased risk of cancer in Asians. However, further detailed studies are still required to confirm our findings.
Keywords: IL-2, polymorphism, cancer, risk, meta-analysis
Methods: A literature search was performed systematically using electronic databases. The odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect.
Results: A total of ten studies including 3,060 cases and 3,435 controls were involved in this meta-analysis. The results indicated that IL-2 -330T/G polymorphism was significantly associated with cancer risk ([OR =2.03, 95% CI =1.40–2.95] for GG vs TT; [OR =1.37, 95% CI =1.11–1.69] for GT vs TT; [OR =1.46, 95% CI =1.18–1.81] for [GG + GT] vs TT; [OR =1.66, 95% CI =1.24–2.23] for GG vs [GT + TT]; and [OR =1.35, 95% CI =1.16–1.57] for G vs T). In the subgroup analysis according to cancer type, significant association was found in lymphoma ([OR =1.46, 95% CI =1.11–1.91] for GT vs TT; [OR =1.58, 95% CI =1.22–2.05] for [GG + GT] vs TT; [OR =1.84, 95% CI =1.22–2.77] for GG vs [GT + TT]) and other cancers, but not in gastric cancer. In the subgroup analysis by ethnicity, the significant risk was found among Asians, but not among Europeans.
Conclusion: This meta-analysis suggests that IL-2 -330T/G polymorphism has an increased risk of cancer in Asians. However, further detailed studies are still required to confirm our findings.
Keywords: IL-2, polymorphism, cancer, risk, meta-analysis
